Hot Biotech Gainers: Sangamo Biosciences (NASDAQ:SGMO), CEL-SCI Corporation (NYSEMKT:CVM), Agios Pharmaceuticals (NASDAQ:AGIO), Lpath (NASDAQ:LPTN)

HIV usually infects blood cells through a protein on their surface, a “docking station” called CCR5. A California company, Sangamo BioSciences Inc. (NASDAQ:SGMO), makes a treatment that can knock out a gene that makes CCR5. Sangamo Biosciences, Inc. (NASDAQ:SGMO) stock performance was 17.08% in last session and finished the day at $22.96. Traded volume was 11.36 million shares in the last session and the average volume of the stock remained 1.08million shares. The beta of the stock remained 1.68. Sangamo Biosciences, Inc. (NASDAQ:SGMO) insider ownership is 1.40%.

Drug maker CEL-SCI Corporation (NYSEMKT:CVM) announced that its first U.S located clinical trial site has been commissioned to conduct its phase 3 tests on its cancer drug injection “Multikine* (Leukocyte Interleukin) which is designed to treat head and neck cancer. CEL-SCI Corporation (NYSEMKT:CVM) rose 12.50 percent to $1.26 yesterday on volume of 3.82million shares. The intra-day range of the stock was $1.13 to $1.30. CEL-SCI Corporation (NYSEMKT:CVM) has a market capitalization of $70.48million.

Stock in Agios Pharmaceuticals Inc (NASDAQ:AGIO) rose by almost a third yesterday after the company announced in its first annual report since going public that it plans to report results from its most advanced cancer drug in about a month. Agios Pharmaceuticals Inc (NASDAQ:AGIO)’s stock on Mar 06, 2014 reported an increase of 26.20% to the closing price of $39.93. Its fifty two weeks range is $15.77 -$44.04. The total market capitalization recorded $1.24billion. The overall volume in the last trading session was 1.12million shares. In its share capital, Agios Pharmaceuticals Inc (NASDAQ:AGIO) has 22.75million outstanding shares.

Lpath, Inc. (NASDAQ:LPTN), the industry leader in bioactive lipid-targeted therapeutics, has brought scientists one step closer to finding a potential treatment for traumatic brain injury (TBI) with a recent publication showing that Lpathomab™, a therapeutic antibody, reverses much of the damage caused by trauma to the nervous system. On Wednesday, shares of
Lpath, Inc. (NASDAQ:LPTN) advanced 6.87% to close the day at $4.82. Company return on investment (ROI) is -36.90% and its monthly performance is recorded as 7.35%. Lpath, Inc. (NASDAQ:LPTN) quarterly revenue growth is 9.30%.